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Abstract
Background: Extracellular matrix remodelling regulated by matrix-metalloproteinase (MMP) inducer (CD147) is a
crucial process during tumor cell invasion and regulation of blood supply. In this study, we evaluated the
correlation of CD147 and MMP-2 expression with major prognostic factors for uveal melanoma and the
development of metastasis.
Methods: The expression of CD147 and MMP-2 was analyzed in 49 samples of uveal melanomas. Triple
immunofluorescence stainings using markers against glial cells (GFAP), endothelial cells (CD34) and macrophages
(CD68) were performed to further analyse the exact localisation of CD147 and MMP-2 positivity. In 28 cases clinical
metastatic disease were found. The remaining 21 cases showed no signs of metastatic disease for an average
follow-up of 10 years. Correlation analysis (Pearson correlation) was performed to analyse the association of CD147
and MMP-2 expression with known prognostic factors, vasculogenic mimicry (VM), the mature vasculature
(von Willebrand Factor) and tumor induced angiogenesis (by means of Endoglin expression).
Results: CD147 and MMP-2 were expressed in 47 (96.0 %) of the uveal melanomas. CD147 up-regulation was
significantly correlated with a higher MMP-2 expression. The overall expression analysis revealed no significant
difference in the metastatic (p = 0.777) and non-metastatic subgroup (p = 0.585). No correlation of CD147 expression
and any system of blood supply was evident. In the non-metastatic sub-group a significant correlation of clustered
CD147 positive cells with largest basal diameter (p = 0.039), height (p = 0.047) and TNM-stage (p = 0.013) was
evident.
Conclusions: These data may indicate that CD147 regulates MMP-2 expression in uveal melanoma cells.
Background
Uveal melanoma is the most frequent primary intraocular
malignancy in Caucasians. Tumor growth is dependent on
the blood supply, which is delivered on the one hand by
angiogenesis. Angiogenesis includes the outgrowth and
proliferation of endothelial cells that remodel the extra-
cellular matrix and align into tube-like structures, and
eventually form functional blood vessels. On the other
hand a supplementary blood supply is present in uveal
melanomas. Maniotis et al. first described the pheno-
menon that highly aggressive and metastatic melanoma
cells form vascular channels lined externally by tumor
cells, which are attached to a basement membrane with-
out the presence of endothelial cells [1]. This process was
termed vasculogenic mimicry (VM). This seems to play a
pivotal role as an alternative pathway when conventional
angiogenesis is inhibited.
During angiogenesis and vasculogenic mimicry extra-
cellular matrix remodelling is a crucial process. It in-
volves numerous extracellular matrices – degrading
enzymes including matrix metalloproteinases (MMPs),
which are believed not only to affect tumor angiogenesis
and VM but also tumor growth, local invasion, and
subsequent distant metastasis [2, 3]. MMPs are metal-
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dependent endopeptidases sharing a common modular
domain structure. They cleave the extracellular matrix
components of the parenchymal and vascular basement
membranes which are normally mechanical barriers to cell
migration and invasion. In tumor local environments
MMPs are usually overproduced; an overexpression of
MMPs have been correlated with tumor vascular density
[2, 3]. In an in vivo tumor model, an increased MMP ac-
tivity was observed in association with tumor angiogenic
potential [4, 5].
MMP stimulation is partly regulated by the extracellu-
lar MMP inducer (EMMPRIN/CD147), a membrane
glycoprotein greatly enriched on the surface of tumor
cells that is known to stimulate tumor and neighbouring
stromal cells, such as fibroblasts and endothelial cells, to
increase their synthesis of several MMPs [6–10].
Previous studies showed that CD147 is present in the
corneal epithelium, stromal keratocytes, endothelial
cells, Bowman membrane in keratoconic corneas, in the
RPE, different retinal layers, and nerve fascicles in the
optic nerve head [11–13]. CD147 expression has been
correlated with invasion and tumor progression in nu-
merous malignant tumor models including melanoma
[14, 15].
So far the CD147 expression and their association with
established prognostic factors, with different modalities
of blood supply as well as the associated target molecule
MMP-2, have not been studied in uveal melanomas.
Therefore, to investigate the CD147 and MMP-2 signal-
ling pathway we evaluated their expression and correlation
with known prognostic factors, VM, the mature vascula-




Paraffin sections from 49 of primary uveal melanoma,
which were pathologically well characterized (See
Table 1), were analyzed retrospectively with respect to
the immunohistological expression of CD147 and
MMP2. Staining for von Willebrand Factor (vWF), a
marker for mature vasculature, was performed to allow
the count of vessels. For visualisation of tumor induced
angiogenesis, immunohistochemical staining for Endo-
glin (CD105) was carried out. During neoplasm-related
angiogenesis the transforming growth factor-β1 and –β3
(TGF- β1, TGF-β3) binding receptor Endoglin is strongly
up-regulated on the endothelium [16, 17]. All the pri-
mary and secondary antibodies used are listed in Table 2,
with the information on their type, source, and dilution
factor, as well as the corresponding pretreatment and
visualisation methods.
The uveal melanomas were obtained by enucleation
from 1982 to 1999 at the University Eye Hospital of
Tübingen (specimens’ use authorized by JMR, head of
ophthalmopathology at the University Eye Hospital of
Tübingen). In 28 cases metastatic disease was found in
the restaging examination. The remaining 21 patients
had a mean follow-up of 10 (6–18) years. Irradiation was
conducted previously in 16 tumors. The non irradiated
tumors received enucleation as primary therapy.
For CD147 and MMP-2 double-immunostainings, ser-
ial paraffin sections were deparaffinized in three changes
of xylol and rehydrated in a graded series of alcohol
(100–50 %). Antigen retrieval was performed by cooking
the slides in citrate puffer for 25 min, followed by cool-
ing down at room temperature for 20 min and washing
three times with phosphate-buffered saline (PBS). After-
wards, sections were incubated with blocking buffer (2 %
bovine serum albumin (w/v) and 20 % rat serum (v/v) in
PBS) for one hour at room temperature followed by the
coincubation with primary CD147 and MMP-2 anti-
bodies (diluted as stated in Table 2 in 3%BSA-0.1 % Tri-
ton X-100 in PBS) overnight at 4 °C. Negative controls
were incubated in the blocking buffer alone. Sections of
mamma carcinoma were incubated with the primary
antibody cocktail as positive control. After rinsing with
PBS, sections were incubated with the corresponding
fluorescence-conjugated secondary antibodies (Table 2)
diluted in 3 % BSA-PBS for 1 h at room temperature
under protection from light. After rinsing with PBS three
times for 5 min, nuclei were counterstained with DAPI
(0.5 μg/ml in PBS, 150 μl per section) for 8 min in the
dark. After rinsing with PBS for 5 min, the slides were
mounted with Mowiol-coated coverslips.
Triple fluorescence-immunostainings were performed
by following the procedure above, by incubating the sec-
tions with a cocktail of primary antibodies against
CD147, MMP-2 and CD34, CD68 or GFAP, followed by
the cocktail of secondary antibodies, which were diluted
in 3 %BSA-0.1 % Triton X-100 in PBS as described in
Table 2.
The Endoglin and vWF immunostainings were per-
formed as described previously [18]. In brief, the sec-
tions were deparaffinized and rehydrated as above. In
order to better visualize the staining, melanin was
bleached by incubating the sections in 3.0 % (v/v) hydro-
gen peroxide, 0.5 % potassium hydrogen phosphate, and
1.0 % (w/v) disodium hydrogen phosphate for 12 h at
room temperature as described previously [19]. The ma-
jority (n = 26) of slides received a bleaching due to the
high level of pigmentation with ranging bleaching times
(mean: 65.2 min) depending on the pigmentation grade.
No background staining arising from endogenous per-
oxidases was detected in the negative controls of the
remaining unbleached slides (data not shown). Anti-
gen retrieval by proteolytic digestion was performed
on the sections that would be processed for Endoglin
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immunostaining by incubation in 0.5 % Pronase (Sigma-
Aldrich, Munich, Germany) in PBS for 30 min. Sections
were incubated with horse serum (15 μl in 1 ml PBS) for
30 min at room temperature, followed by the primary anti-
bodies against human Endoglin or vWF (Table 2) for 12 h
at 4 °C. Appropriate normal serum instead of the primary
antibodies was added for negative controls. Paraffin sec-
tions of eyes that have shown a high positivity in a previous
staining served as positive controls. After three washes for
5 min in PBS, sections were incubated with horseradish
peroxidase-conjugated secondary antibodies for 1 h at
room temperature. Before counterstaining with Mayer’s
hematoxylin and coverslipping the slides were washed
in PBS and developed with 3-Diaminobenzidine (Fluka,
Buchs, Switzerland).
To visualize VM CD31/PAS-immunostaining was per-
formed as previously described [18]. In brief, sections were
deparaffinized and bleached as above. Antigen retrieval
was performed by cooking the sections in Tris-buffered
saline (TBS) for 30 min. After blocking with horse serum
(15 μl in 1 ml TBS) for 60 min, sections were incubated
with the primary antibodies against CD31, followed by the
horseradish peroxidase-conjugated secondary antibodies
(Table 2) for 1 h at room temperature each. After three
rinses for 5 min in PBS, sections were developed with 3-
Diaminobenzidine (Fluka, Buchs, Switzerland), counter-
stained with periodic acid-Schiff, and coverslipped. Nega-
tive controls of the tumor sections and gastric mucosa
were treated with normal sera instead of antibodies and all
exhibited a negative staining (data not shown).
Table 1 Clinical data of the patients and histological characteristics of the uveal melanomas
Variable Total Metastasis No metastasis P-Wert (Spearman’s Rho Test)
p-value r-value
Number of patients 49 28 21
Sex
Female 21 (42.9 %) 13 (26.5 %) 8 (16.3 %) 0.894 −0.019
Male 28 (57.1 %) 15 (30.6 %) 13 (26.5 %)
LTD (mm)
Median 15a 15.5b 15b 0.164 0.208
Range 5–30 10–30 5–28
Height (mm)
Median 7c 7.5a 6b 0.263 0.175
Range 2–22 2- 2–12
Ciliary body invasion 22d (44.9 %) 16 (57.1 %) 6d (28.6%) 0.108 0.230
Scleral invasion 46d (93.9 %) 26 (92.9 %) 20d (95.2 %) 0.247 −0.149
Extrascleral extension 7e (14.3 %) 5d (17.9 %) 2d (9.5 %) 0.058 −0.282
Invasion
of Bruch’s membrane 27d (55.1 %) 16 (57.1 %) 11d (52.4 %) 0.732 0.050
of the optic nerve head 2d (4.1 %) 1 (3.6 %) 1d (4.7 %) 0.560 −0.088
Histological subtype
Epithelioid 9 (18.4 %) 8 (28.6 %) 0 (0 %) 0.005 0.387
Mixed 22 (44.9 %) 12 (42.9 %) 11 (52.4 %)
Spindle cell 18 (36.7 %) 8 (28.6 %) 10 (47.6 %)
TNM
Stage I 5f (10.9 %) 0d (0.0 %) 5c (26.3 %) 0.073 0.264
Stage II 10 (21.7 %) 6 (22.2 %) 4 (21.1 %)
Stage III 16 (34.8 %) 11 (40.7 %) 5 (26.3 %)
Stage IV 15 (32.6 %) 10 (37.0 %) 5 (26.3 %)
High CD105 expression 26d (54.2 %) 18d (66.7 %) 8 (38.1 %) 0.098 0.237
High vWF expression 26 (53.1 %) 18 (64.3 %) 8 (21.1 %) 0.129 0.216
VM 25 (51.0%) 19 (67. %) 6 (28.6 %) 0.016 0.342
LTD largest tumor diameter, mm Millimeter, TNM Tumor Node Metastasis, CD105 Endoglin, vWF von Willebrand Factor, VM Vasculogenic Mimicry
a4 missing values, b2 missing values, c6 missing values, d1 missing value, e2 missing values, f3 missing values
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Image analysis
Three days after immunohistochemistry, images were
acquired using a fluorescence microscope (Leica DMI
6000B, Solms, Germany connected to a digital camera
(Leica DFC 290, Solms, Germany) and the correspond-
ing filters (A4: Ex: 360/40, Em: 470/40 nm; L5: Ex: 460/
40, Em: 527/30 nm; Y3: Ex: 545/30, Em: 610/75 nm; Y5:
Ex: 620/60, Em: 700/75 nm). All tumor samples were
initially observed under 100X magnification to evaluate
the homogeneity of CD147 and MMP-2 stainings. For
the quantification of CD147 and MMP-2 expression,
images from n = 10 random fields of 0.04 mm2 (400X
magnification) were acquired, ensuring that the images
are representative of the areas exhibiting different in-
tensities in the case of tumors having inhomogeneous
antigen expression. Quantifications were performed
using the ImageJ Software (National Institute of Mental
Health, Bethesda, Maryland, USA) by two independent
observers (JL, VV), who were totally masked to the
follow-up of the patients. Evaluation of the antigen ex-
pression in tumor samples was conducted in 10 random
fields of 0.04 mm2 (400X magnification) with the ImageJ
Software (National Institute of Mental Health, Bethesda,
Maryland, USA) by two independent observers (JL, VV)
who were totally masked to the follow-up of the pa-
tients. Additionally, the presence of clustered CD147
positive cells was evaluated: (no: 0, moderate number: 1,
or high number: 2).
The objective evaluation of the fluorescence intensity
was performed using the ImageJ software. Ten images
were summarized as image stack and a grid was placed
over the pictures with an edge length of 3.5 in. resulting
in 680 rectangles. A rectangle was counted as positive if
50 % of the area was positive. The intensity of the pixels
in stack was calculated according to the formula: V =
(R + G + B)/3. At the end of the calculation, the per-
centage mean intensity was calculated from the mean
of the intensity of stained areas for each marker. The
intensity was then classified: (no expression: no posi-
tive cells (0), low intensity (1): 1–24 %, moderate in-
tensity (2): 25–50 %, high intensity (3): 51–75 %, very
high intensity (4): 76–100 %). The following formula
was used for calculating the objective expression rate:
100/16 x cell count x intensity score.
To evaluate the status of mature vasculature and
angiogenesis the number of all vWF and Endoglin positive
cells was evaluated in n = 3 of the 10 images (0.04 mm2)
exhibiting the highest level of expression according to the
following grading system: no expression: no positive
cells, low/moderate expression: 1–50 %, high expression:
51–100 %) as reported previously [18].
The analysis of VM two independent observers (JL,
VV) analyzed the CD31 and PAS stained uveal melan-
oma specimens under 200x and 400x magnification
(Leica DMI 6000B, Solms, Germany) and assigned the
tumors to be VM positive or VM negative. A positive
rating was given in case of vascular channel formation
as reported previously [1]. An example is shown in Fig. 1.
Sections with different rates by first and second observer
were re-evaluated to come to a final decision.
Table 2 Summary of the applied primary and secondary antibodies
Primary antibodies
Antigen Source Dilution Clone Manufacturer Pre-treatment Visualisation
CD147 Mouse 1:50 P Abcam, Cambridge, UK Cooked in citrate puffer Fluorescence
(Alexa Fluor® 488)
MMP-2 Rabbit 1:100 P Abcam, Cambridge, UK Cooked in citrate puffer Fluorescence (Cy3)
CD34 Rat 1:100 Clone MEC 14.7 Abcam, Cambridge, UK Cooked in citrate puffer Fluorescence (Cy5)
CD68 Rat 1:100 Clone FA-11 Abcam, Cambridge, UK Cooked in citrate puffer Fluorescence (Cy5)
GFAP Chicken 1:1000 P Abcam, Cambridge, UK Cooked in citrate puffer Fluorescence
(Alexa Fluor® 647)
Endoglin Mouse 1:5 Clone SN66 Dako, Glostrup, Denmark 100 mg Protease in 200 ml TBS Chromogenic (HRP, DAB)
vWF Mouse 1:50 Clone F8/86 Dako, Glostrup, Denmark 100 mg Protease in 200 ml TBS Chromogenic (HRP, DAB)
CD31 Mouse 1:40 Clone JC704 Dako, Glostrup, Denmark Cooked in TBS Chromogenic (HRP, DAB)
Secondary antibodies
Reactivity Source Dilution Clone Conjugation Manufacturer
Mouse IgG (H + L) Goat 1:50 P Alexa Fluor® 488 Molecular Probes®- Invitrogen, Eugene,USA
Rabbit IgG (H + L) Goat 1:50 P Cy3 Dianova, Hamburg, Germany
Rat IgG (H + L) Donkey 1:50 P Cy5 Dianova, Hamburg, Germany
Chicken IgY (H + L) Goat 1:50 P Alexa Fluor® 647 Dianova, Hamburg, Germany
Mouse IgG Goat 1:250 P HRP Dianova, Hamburg, Germany
DAB 3,3′-Diaminobenzidine, HRP Horseradish peroxidase, P Polyclonal, TBS Tris-buffered saline
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Statistics
The data were described by means and standard deviation
(±SD). A Mann–Whitney-U test and a correlation analysis
(Pearson correlation) were performed to show the associ-
ation of the expression rate with prognosis using the SPSS
software (Version 16, Icn, Chicago, Illinois, USA).
Results
CD147 expression in primary uveal melanoma
In this tumor series CD147 was expressed by 47 (96.0 %)
primary uveal melanomas especially at the cell surface.
The percentage fraction of positive cells according to the
objective cell-count varied between 1.07 % and 100 %
(mean: 37.12 %). Particularly in large tumors (LTD >
12 mm), most cells at the tumor margin exhibited a
higher degree of expression compared to the cells in the
inner regions (Fig. 2). In the primary tumor a weak
colocalisation of CD147 and MMP-2 was observed in
some CD68 positive cells, which were probably
tumor-infiltrating macrophages (Fig. 3c). There was
no significant difference according to the overall ob-
jective or subjective expression of CD147 in the uveal
melanomas which did or did not develop metastatic
disease in the further clinical course. The complete data
and p-values of the objective evaluation are summarized
in Table 3. The correlation with known prognostic factors
(age, gender, radiation, cell type, invasion of the ciliary
body, largest tumor diameter (LTD), height, TNM-
classification, invasion of Bruch’s membrane, intrascleral
invasion, extrascleral extension, invasion of the optic
nerve) revealed no significant association with the overall
expression analysis (Pearson correlation, p < 0.05).
A closer look at the distribution of CD147 expression
at higher magnification (400X) revealed that the majority
of positive cells had a homogenous distribution and
intensity within randomly selected fields (0.04 mm2,
Fig. 2b and c). However, in 29 uveal melanomas (59.2 %)
nested neoplastic cells were highly positive for CD147.
The vast majority of these tumors with clustered CD147
positive cells (n = 24) developed metastasis in the further
clinical course but the level of significance was not
reached (p = 0.145) (Fig. 4). Nevertheless, in the non-
metastatic sub-group, a significant correlation of clus-
tered CD147 positive cells with LTD (p = 0.039), height
(p = 0.047) and TNM-stage (p = 0.013) was evident. In
the metastatic sub-group the presence of nested CD147
positive cells was correlated with ciliary body involvement
(p = 0.042).
CD147 expression in the eye
In 35 % of the examined eyes a low or moderate CD147
expression was observed in the retina especially in the
nuclear layers (Fig. 5). Coimmunostainings for CD147
and GFAP or CD68 demonstrated that some astrocytes
in the nerve fiber layer, Müller cells, and CD68-positive
microglia were also expressing CD147 in the retina,
whereas the retinal endothelial cells (detected by anti-
bodies against CD34) exhibited a weaker CD147 expres-
sion (Fig. 5). The epithelium of the ciliary body expressed
CD147 in 15 % of the cases. The corneal endothelium and
epithelium revealed a very low CD147 expression in 21 %
of the documented cases. The remaining cases expressed
no CD147 in the above mentioned ocular structures
(Fig. 5).
MMP-2 expression in primary uveal melanoma
MMP-2 was expressed by 47 of the 49 examined uveal
melanomas in this study (96.0 %). An average of 89.3 %
tumor cells showed MMP-2 expression (range: 3.26–
100 %). In some large tumors (LTD > 12), cells at the
tumor margin exhibited a higher degree of immunoreac-
tivity compared to the cells in the inner regions (Fig. 1).
A difference in the MMP-2 expression of tumors with or
without metastatic disease could not be shown (Table 4).
The correlation analysis of MMP-2 expression with
known prognostic factors (age, gender, radiation, cell
type, invasion of the ciliary body, largest tumor diameter,
tumor height, TNM-classification, invasion of Bruch’s
membrane, intrascleral invasion, extrascleral extension,
invasion of the optic nerve) revealed no significant
association (Pearson-correlation, p < 0.05). Although an
increased MMP-2 expression was observed in tumors
which formed VM the level of significance was not
reached (p = 0.073).
In the detailed analysis of the distribution of MMP-2
positive cells, an up-regulation was observed in the area
of the nested uveal melanoma cells which were highly
positive for CD147 (Fig. 4). Beside the overall expression
Fig. 1 Immunofluorescence microphotography of CD31/PAS-staining
demonstrating a VM typical loop. Part of a PAS positive channel
containing red blood cells is marked with an arrow
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analysis revealed a positive correlation of those two
markers (p < 0.001).
MMP-2 expression in the eye
A low MMP-2 positivity was evident in some cases of the
documented corneal endothelium (40 %) and epithelium
(29 %). The remaining cases expressed no MMP-2. In
69 % of the examined eyes a low or moderate MMP-2 ex-
pression was observed in the retinal pigment epithelium
and the detached retina associated with the uveal
melanoma (Fig. 5). The retinal staining was evident
particularly in the nuclear layers but also in some
Fig. 2 Expression of CD147 and MMP-2 in a primary uveal melanoma sample analyzed by fluorescence double-immunohistochemistry. a A mosaic
image was constructed from n = 96 images acquired at 50X magnification to demonstrate the expression of CD147 (green) and MMP-2 (red) in the
whole tumor (67 year old female patient who developed metastasis after 6 years of follow-up). The nuclei were counterstained with DAPI. The upper
white square on the merged image demonstrates the approximate location of the images which are presented in panels B and D. The lower white
square demonstrates the approximate location of the images presented in panel C. R: Retina, C: Choroid. Scale bar: 2 mm. b, c Focused
images acquired at 400X magnification, which demonstrate a strong expression of CD147 and MMP-2 at the tumor margin, and a weaker
expression in the inner regions, respectively. Scale bars: 25 μm. d Images of the negative control which was performed by omitting the
primary polyclonal CD147 and MMP-2 antibodies. Scale bars (a-d): 25 μm. e Expression of Endoglin and vWF in the same tumor sample.
Scale bars: 100 μm
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Fig. 3 Origins of the cells exhibiting CD147 and MMP-2 expression in the uveal melanoma and retina. a Triple immunostainings for CD147,
MMP-2, and the glial marker GFAP demonstrate the expression of the former two proteins in some astrocytes in the nerve fiber layer (NFL)
and Müller cells (arrows) in the detached retina (R) above the tumor, whereas no GFAP positive cells were detected in the tumor (UM). b Triple
immunostainings for CD147, MMP-2, and the endothelial marker CD34 demonstrate a strong expression of MMP-2 in some endothelial cells (arrows)
in the detached retina (R). c Triple immunostainings for CD147, MMP-2 and the macrophage/fibroblast marker CD68 demonstrate the strong expression
of CD147 in some microglia (arrows) in the detached retina (R). Some CD68-positive cells, which were likely to be tumor infiltrating macrophages, also
exhibited a coexpression of CD147 and MMP-2 in the tumor (UM, arrows). ONL: Outer nuclear layer, INL: Inner nuclear layer. The negative (−) control
was performed by the omission of all the three primary antibodies within a group. Scale bars: 25 μm









Objective number of positive cells (stage 1–4) mean ± SD 3.6 ± 0.74 1.4 ± 1.03 3.8 ± 0.34
Objective intensity (stage 1–4) mean ± SD 2.8 ± 0.64 3.6 ± 0.92 1.82 ± 0.95 0.788
Rate of objective expression (%) mean ± SD 37.1 ± 25.61 % 32.6 ± 26.05 % 43.2 ± 24.28 % 0.777
SD standard deviation
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astrocytes, Müller cells, and retinal endothelial cells
(Fig. 5). The epithelium of the ciliary body expressed
MMP-2 in 40 % of the cases (Fig. 5).
Discussion
Tumor cell invasion and metastasis formation include the
ability of tumor cells to dissolute the extracellular matrix
and migrate through the digested barrier. The mechanism
of degradation of the connective tissues by uveal melan-
oma cells is poorly understood but is likely to be mediated
by a variety of enzymes, including matrix metalloprotein-
ases (MMPs) and are possibly regulated by CD147 which
induces MMPs expression. CD147 is over-expressed in
various cancerous tissues [9, 11, 20]. In cutaneous melan-
oma tissue Kanekura et al. were able to show that CD147
expression correlates with advanced tumor stage or size
and is associated with a poor prognosis [15].
So far the expression of CD147 has not been studied
in uveal melanomas. This study is the first to report on
the expression profile of CD147 in metastatic and non-
metastatic uveal melanomas. CD147 expression was ob-
served in 47 (96.0 %) of the examined uveal melanomas.
In average 37.12 % of the uveal melanoma cells were
positive for CD147 (1.1–99 %). No significant association
with the formation of metastasis was observed in the
overall expression analysis of CD147.
Van den Oord et al. described in a series of malignant
and non-malignant cutaneous lesions that MMP and
CD147 immunoreactive cells were strikingly nested and
alternated with unstained neoplastic cells [21]. This
underlines the phenotypical heterogeneity among cuta-
neous melanoma cells within the same stage of tumor
progression [22].
In view of these findings we screened the uveal melan-
oma regarding the presence of nested positive uveal
melanoma cells. The presence of clustered CD147 positive
uveal melanoma cells was more often observed in meta-
static uveal melanomas, but the level of significance was
not reached. Nevertheless, a sub-group analysis revealed a
significant correlation of clustered CD147 positive cells
with prognostic factors such as either LTD, tumor height,
TNM-stage in the non-metastatic group or ciliary body
involvement in the metastatic group.
Previous studies reported that CD147 expression level
was not related to the age of the cancer patient, tumor
type or gross morphology. But Zhang et al. reported on
a positive correlation of CD147 expression with tumor
histopathologic type and clinical stage of disease in a
Fig. 4 Immunofluorescence microphotography (400x magnification field of view) of (a) a spindle cell melanoma of a 69 year old female patient
(LTD: 5 mm) revealed clustered CD147 positive cells which were associated with MMP-2 up-regulation. No metastasic disease was detected clinically
during a follow-up of 9 years. In a mixed cell uveal melanoma (b) nested CD147 positive cells were detected which were also associated with MMP-2
upregulation. This 90 year old patient presented with metastastic disease one year after enucleation. c No signals were detected in the negative
controls performed by omitting the primary polyclonal CD147 and MMP-2 antibodies. Scale bar: 25 μm
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series of squamous cell carcinoma [23, 24] as observed
in our series of uveal melanomas.
Nevertheless the exact mechanism of metastasis forma-
tion and the exact impact of CD147 is still unknown. In
our study nested uveal melanoma cells expressed CD147
especially at the cell surface. CD147 seems to require
direct cell-cell contacts to stimulate collagenolytic activity,
CD147 on melanoma cells might act on neighbouring neo-
plastic cells to induce the release of enzymes necessary for
the breakdown of matrix components as already proposed
Fig. 5 Immunofluorescence microphotography (100x magnification field of view) of the retina (a) revealed an MMP-2 upregulation in all retinal
layers with a lower density in the outer plexiform layer. CD147 was especially upregulated in the outer and inner nuclear layer. The epithelium of
the ciliary body (b) revealed a moderate MMP-2 expression especially at the cell surface while CD147 was expressed in a low manner. The negative
controls were performed by omitting the polyclonal primary CD147 and MMP-2 antibodies. Corneal epithelium revealed CD147 positivity in contrast
to the stroma of the cornea (c). Scale bars: 100 μm









Objective number of positive cells (stage 1–4) mean ± SD 3.6 ± 0.89 3.7 ± 0.82 3.6 ± 1.00
Objective intensity (stage 1–4) mean ± SD 1.3 ± 0.87 1.2 ± 0.86 1.5 ± 0.87 0.292
Rate of objective expression (%) mean ± SD 31.0 ± 21.93 % 27.6 ± 21.01 % 35.4 ± 22.84 % 0.585
SD standard deviation
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by van den Oord et al. based on their observation in
pigmented skin lesions [21]. Additionally, we observed an
up-regulation of CD147 and MMP-2 associated with CD68
positive cells as shown previously for other tumours.
These results indicate a mechanism whereby tumour
cell-macrophage interactions induce the EMMPRIN-
MMP pathway as supposed by Amit-Cohen et al. [25].
Accordingly, our findings confirm that an increased
CD147 expression was significantly associated with an
increased MMP-2 expression. This relationship was de-
scribed for different tumors but not for the uveal melan-
oma so far. Previous studies demonstrated that CD147 is
involved in regulation of tumour progression including
growth, invasion and metastasis formation via induction
of MMPs secretion from surrounding fibroblasts [26, 27].
Wysocki reported that CD147 which was purified from
hepatocellular cancer (HCC) cells stimulates human fibro-
blasts to produce MMP-2 and MMP-9 [28]. HCC cells
with silenced MMP-2 and MMP-9 genes were less inva-
sive compared to MMP-2 and MMP-9 silenced fibroblasts
or CD147-silenced HCC cells when co-cultured with fi-
broblasts [26, 29]. The use of siRNA, a specific antibody,
or arsenic trioxide to block CD147, decreases the MMP-2
and MMP-9 secretion resulting in an inhibition of migra-
tion and invasion of HCC [26, 30]. Therefore, the pre-
sumed regulative relationship of these two proteins might
also apply to uveal melanomas.
The CD147 induced up-regulation seems to be a key
event during vasculogenic mimicry formation in tumors
as demonstrated in a previous study for ovarian cancer
cells [31]. According to these findings we also observed
a non-significant up-regulation of MMP-2 in VM posi-
tive uveal melanomas, which may indicate a prominent
relevance of MMP-2 for VM. Besides, due to its protease
function MMP-2 has a crucial role during the degradation
of extracellular matrix (ECM) which results in the reduc-
tion of adhesive strength between tumor cells, induction
of migration, and potentially metastasis formation [32, 33].
An increase of MMPs expression was observed in a
number of tumors during progression. Especially higher
MMP-2 and MMP-9 expression was correlated with inva-
sive and metastatic tumor properties [34, 35]. A number
of different tumors such as of the colorectum [36], breast
[37], lung [38], liver [39], skin [40], prostate [41], and
ovary [42] reveal an elevated MMP-2 level. Cottam et al.
reported on an increased MMP-2 secretion in different
uveal melanoma cell lines [43]. Additionally, findings of an
in vitro study indicate that the activated MMP-2 expres-
sion may be associated with uveal melanoma progression
[44]. An immunohistochemical analyse of 29 uveal melan-
oma specimens revealed an association of an increased
MMP-2 expression with a worse prognosis [45]. In our
series of uveal melanomas no significant association of
MMP-2 expression and prognosis was evident.
CD147 is proposed not only to be involved in vasculo-
genic mimicry formation but also in the regulation of
angiogenesis via VEGFR-2. Tang et al. have recently re-
ported that the up-regulation of EMMPRIN in MDA-
MB231 breast tumor cells can also increase VEGF ex-
pression in these cells, which can then act in a paracrine
manner on endothelial cells to promote tumor angiogen-
esis. Similarly, EMMPRIN seems to promote melanoma
cell invasion and disease progression by stimulating the
VEGF/VEGFR-2 autocrine loop in two cutaneous melan-
oma cell models [46]. Hypoxia itself may enhance the
CD147 induced MMP-2 expression, the invasive and
metastatic potential of cutaneous melanoma cells as pre-
sumed by Bougatef et al. [47]. Besides Desch et al. postu-
late that MMP-2 itself apparently plays a central role in
the autocrine regulation of VEGF-A secretion at the
transcription level and expression which directly tar-
gets VEGFR-2 leading to endothelial cell activation in
cutaneous melanoma cell lines [48]. In our series of
49 uveal melanomas no significant association of CD147
or MMP-2 expression with tumor associated angiogenesis
by means of Endoglin expression or the vWF expres-
sion itself was observed. This might be due to the ad-
vanced stage of evaluated uveal melanoma tissues
with a mean size of 15.5 mm. In these cases the rapid
growth phase and therefore the process of tumor in-
duced neovascularisation might be already completed
which is a hypothesis already proposed for cutaneous
melanoma [49].
The additional analysis of MMP-2 expression in this
series of eyes with uveal melanomas revealed an upregula-
tion of MMP-2 in the retina under ischemia or induced by
reperfusion injury, oxidative stress which both may occur
in the case of retinal detachment and mechanical stretch-
ing as described in previous studies [50–53] due to the
tumor growth underneath.
Conclusions
In summary, CD147 up-regulation was significantly
correlated with a higher MMP-2 expression in this series
of uveal melanoma. The presence of clustered CD147 in
uveal melanomas was significantly associated with tumor
stage in the non-metastatic subgroup.
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